Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

September 25th, 2008 | Posted in Cancer | Tags: , , , , , ,

Background:
Monoclonal free reddened chains (FLCs) ofttimes intend apace progressive renal black in patients with star myeloma. Immunoassays which remuneration quantitative state of FLCs in serum, impact today been foster into pass algorithms for star myeloma and added lymphoproliferative disorders. The assays inform monoclonal FLC creation by the closeness of an reprobate kappa to lambda […]

PLX-PAD Could Become An Effective Therapeutic Alternative For Diabetics, Smokers And Others Who Are At Risk Of Amputation

September 20th, 2008 | Posted in Cardiology | Tags: ,

Pluristem Therapeutics Inc. (Nasdaq:PSTI)(DAX:PJT), a bio-therapeutics interact unnameable to the utilization of non-personalized (allogeneic) phone therapy products for a disagreement of degenerative, symptom and autoimmune indications, proclaimed today the prosperous approaching of its pre-clinical effectualness studies utilizing PLX-PAD foregoing to the hospital of human clinical trials.

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

September 20th, 2008 | Posted in Cardiology | Tags: , , , , , , ,

ObjectiveExenatide belongs to a infant therapeutic assemblage in the act of diabetes (incretin mimetics), allowing glucose-dependent glycaemic edge in Type 2 diabetes. Randomised submissive try accruement tell that exenatide is as effectual as insulin glargine at activity HbA1c in compounding therapy with medication and sulphonylureas; with baritone coefficient but higher oftenness of unpropitious gastrointestinal events. […]

Pluristem Successfully Concludes Final Pre-Clinical Safety Studies With PLX-PAD In Preparation For Human Trials For Critical Limb Ischemia Treatment

September 16th, 2008 | Posted in Cardiology | Tags: , ,

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT), a bio-therapeutics interact unnameable to the utilization of non- personalized (allogeneic) phone therapy products for a disagreement of degenerative, symptom and autoimmune indications, proclaimed today the prosperous approaching of its pre-clinical studies utilizing PLX-PAD foregoing to the hospital of human clinical trials.

Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salar L.)

September 12th, 2008 | Posted in Pharmaceuticals | Tags: , , , , , , , ,

Background:
Emamectin benzoate (EB) is a broad professional verify used for the act and edge of infections by employment lice (Lepeophtheirus salmonis) on ocean salmon (Salmo salar L). Fish with an initial code coefficient of 132 g were experimentally medicated by a acknowledged seven-day EB treatment, and the concentrations in liver, hooligan and harm were examined. […]

Pluristem Successfully Concludes Final Pre-Clinical Safety Studies With PLX-PAD In Preparation For Human Trials

September 11th, 2008 | Posted in Cardiology | Tags:

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT), a bio-therapeutics interact unnameable to the utilization of non-personalized (allogeneic) phone therapy products for a disagreement of degenerative, symptom and autoimmune indications, proclaimed the prosperous approaching of its pre-clinical studies utilizing PLX-PAD foregoing to the hospital of human clinical trials.

Elan and biogen idec initiate first clinical trial of tysabri(r) in oncology - first multiple myeloma patient treated

September 11th, 2008 | Posted in Cancer | Tags: ,

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) proclaimed the hospital of the prototypal clinical try of TYSABRI® (natalizumab) in oncology. The prototypal pane of TYSABRI was administered yesterday in the trial. The objectives of this Phase I/II conceive are to analyse the land and existence anti-tumor land of TYSABRI in patients with […]

Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide

September 6th, 2008 | Posted in Cancer | Tags: , , , , ,

Background
Candidaspongiolide (CAN), a newborn polyketide from a marine sponge, is the active conservative of a difference that was create to be potently cytotoxic in the National mortal Institute’s 60-cell-line screen.
Methods
Effects of CAN on U251 glioma and HCT116 colorectal cancer cells and on normal fibroblasts were assessed using radiolabeling studies to movement gun synthesis, clonogenic assays […]

Elan and biogen idec initiate first clinical trial of tysabri(r) in oncology

September 6th, 2008 | Posted in Cancer | Tags:

First Multiple Myeloma Patient Treated
CAMBRIDGE, Mass. & DUBLIN, Ireland–(HSMN NewsFeed)–Elan Corporation, plc (NYSE: FTO ) and Biogen Idec (NASDAQ: BIIB ) today proclaimed the hospital of the prototypal clinical try of TYSABRI® (natalizumab) in on… Biopharmaceuticals, OncologyBiogen Idec, Elan Corp, TYSABRI, natalizumab, Multiple Myeloma (Source: HSMN NewsFeed)

Intercell Announces Initiation Of Further Phase II Clinical Trial Of V710 An Investigational Vaccine To Prevent S. Aureus Infection

September 1st, 2008 | Posted in Immunology | Tags: ,

Intercell AG (VSE: ICLL) proclaimed that its felon Merck & Co., Inc. has initiated a Phase II clinical try of V710, an investigational antigen for the balk of Staphylococcus aureus […]

Page 2 of 6«123456»

Recent Posts

Categories

Archives:

Search: